LCAT and cholestasis: In recent years, instead, several LCAT-raising biologic approaches (recombinant human LCAT or rhLCAT), direct or indirect gene therapies, peptide activators, and small molecules are currently under development as potential therapeutics for cholestasis, especially when it reaches such high levels that it causes hyperviscosity syndrome, requiring plasmapheresis [61].